Welcome!

News Feed Item

Eisai Announces Launch of Vascular Embolization Device DC Bead(R) in Japan

Tokyo, Feb 3, 2014 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch the vascular embolization device DC Bead(R) (specially controlled medical device) in Japan on February 4.

DC Bead contains hydrophilic microspheres made from cross-linked polyvinyl alcohol polymer. Developed by Biocompatibles UK Limited (Biocompatibles), a BTG International group company, as an intravascular embolization device, it is injected via catheter into targeted blood vessels to achieve selective embolization. DC Bead is already marketed as an effective embolization device in the treatment of hepatocellular carcinoma (HCC) and other hypervascularized tumors in more than 50 countries and territories worldwide, including in Europe and the United States.

Eisai acquired the exclusive rights to develop and market DC Bead in Japan from Biocompatibles in July 2009 and received manufacturing and marketing authorization for the device from Japan's Ministry of Health, Labour and Welfare in April 2013 for use in transcatheter arterial embolization (TAE) in patients with HCC. On February 1, 2014, DC Bead was classified in the Special Treatment Materials (STM) category for medical device reimbursement under the country's National Health Insurance system.

In Japan, the Eisai Group markets a diverse range of medical devices and pharmaceuticals for the diagnosis and treatment of liver diseases. These products include the non-ionic contrast medium Iomeron(R) and non-ionic contrast medium for MRI ProHance(R), both of which are imaging devices used in HCC diagnosis, the in-vitro diagnostic tool PIVKA-II Kit, which is used to measure the HCC marker PIVKA-II/DCP, and two liver disease medications and anti-allergy agents, Stronger Neo-Minophagen(R) C and Glycyron(R) Tablets. Through the launch of DC Bead in Japan, Eisai seeks to further enhance its liver disease product portfolio in the country as well as continue to contribute to addressing the diverse needs of, and increasing the benefits provided to, patients with HCC and their families.

About DC Bead

DC Bead contains hydrophilic microspheres (beads) produced made from cross-linked polyvinyl alcohol polymer. As a vascular embolization device, it is injected via catheter into targeted blood vessels to achieve selective embolization. Due to the beads being both microscopic and uniformly spherical, DC Bead allows for sustained embolization of targeted blood vessels based on vascular diameter and tumor size, with each embolization procedure confirmed through endoscopic observation of the targeted vessels. Following its launch in Japan, the device will be domestically available in three bead sizes (100-300 micro-m, 300-500 micro-m, and 500-700 micro-m) so that an appropriate bead size can be selected based on vascular diameter, tumor size and extent of intended embolization in the targeted blood vessel.

In addition to DC Bead's indication in Japan for transcatheter arterial embolization (TAE) therapy in patients with hepatocellular carcinoma (HCC), Eisai is currently conducting Phase III clinical trials of DC Bead in Japan as an effective embolization device for treating other hypervascularized tumors.
Hypervascularized tumors most commonly refer to hepatocellular carcinoma (HCC), renal cell carcinoma, bone and soft tissue sarcoma, and other tumors that receive nourishment via a sophisticated vascular network formed in tumor tissue.

About Transcatheter Arterial Embolization (TAE)

TAE is a therapy that selectively obstructs blood circulation to induce necrosis in hepatocellular carcinoma (HCC) by injecting embolization material into the hepatic artery, the artery that supplies nutrient blood to the tumor. In contrast to healthy liver cells, which receive blood from both the hepatic artery and portal vein, HCC cells receive blood mainly from the hepatic artery via a vascular network formed in the tumor tissue.

Consequently, by using embolizing material to selectively embolize blood vessels in the hepatic artery, selective necrosis can be more effectively induced at the tumor site. There are two types of TAE therapy: one involving embolization without chemotherapy, and transcatheter arterial chemo-embolization (TACE), the latter of which is performed in combination with chemotherapeutic agents to suppress cancer cell activity.

About Eisai

Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.



Source: Eisai

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Copyright 2014 JCN Newswire. All rights reserved. www.japancorp.net

More Stories By JCN Newswire

Copyright 2008 JCN Newswire. All rights reserved. Republication or redistribution of JCN Newswire content is expressly prohibited without the prior written consent of JCN Newswire. JCN Newswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Carbonite will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Carbonite protects your entire IT footprint with the right level of protection for each workload, ensuring lower costs and dependable solutions with DoubleTake and Evault.
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 21st International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @ThingsExpo Silicon Valley Call for Papers is now open.
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend @CloudExpo | @ThingsExpo, June 6-8, 2017, at the Javits Center in New York City, NY and October 31 - November 2, 2017, Santa Clara Convention Center, CA. Learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
SYS-CON Events announced today that Twistlock, the leading provider of cloud container security solutions, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Twistlock is the industry's first enterprise security suite for container security. Twistlock's technology addresses risks on the host and within the application of the container, enabling enterprises to consistently enforce security policies, monitor...
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deli...
The hot topics in the industry today seem to center around Digital Transformation and Mobile Apps. While a digital transformation strategy is crucial to keep up with the chaos in your industry, customer demands, and other disruptions, the need to create mobile apps to remain relevant in your market and to your customers is equally a no-brainer. Regardless of the approach, the next question always seems to pop up: What architecture should I chose? Native? Hybrid? Managed? Hosted?
We build IoT infrastructure products - when you have to integrate different devices, different systems and cloud you have to build an application to do that but we eliminate the need to build an application. Our products can integrate any device, any system, any cloud regardless of protocol," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA
SYS-CON Events announced today that EARP Integration will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. EARP Integration is a passionate software house. Since its inception in 2009 the company successfully delivers smart solutions for cities and factories that start their digital transformation. EARP provides bespoke solutions like, for example, advanced enterprise portals, business intelligence systems an...
The 21st International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists will examine how DevOps helps to meet th...
SYS-CON Events announced today that Ocean9will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Ocean9 provides cloud services for Backup, Disaster Recovery (DRaaS) and instant Innovation, and redefines enterprise infrastructure with its cloud native subscription offerings for mission critical SAP workloads.
SYS-CON Events announced today that CollabNet, a global leader in enterprise software development, release automation and DevOps solutions, will be a Bronze Sponsor of SYS-CON's 20th International Cloud Expo®, taking place from June 6-8, 2017, at the Javits Center in New York City, NY. CollabNet offers a broad range of solutions with the mission of helping modern organizations deliver quality software at speed. The company’s latest innovation, the DevOps Lifecycle Manager (DLM), supports Value S...
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory?